Positive overall survival results from the Phase III HarMONi-GI1 trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract cancer, presented at the ESMO 2026 Presidential Symposium - The company announces Durvalumab Plus Chemotherapy in First-Line Biliary Tract cancer presented at the ESMO 2026 Presidential Symposium.

Positive overall survival results from the Phase III HarMONi-GI1 trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract cancer, presented at the ESMO 2026 Presidential Symposium - The company announces Durvalumab Plus Chemotherapy in First-Line Biliary Tract cancer presented at the ESMO 2026 Presidential Symposium.